keyword
MENU ▼
Read by QxMD icon Read
search

alopecia guidelines

keyword
https://www.readbyqxmd.com/read/28182134/differential-pharmacology-and-clinical-utility-of-sonidegib-in-advanced-basal-cell-carcinoma
#1
REVIEW
Mohd Wahid, Arshad Jawed, Sajad Ahmad Dar, Raju K Mandal, Shafiul Haque
Patients suffering from advanced basal cell carcinoma (BCC) have very limited treatment options. Sonidegib selectively inhibits the growth of Hedgehog pathway-dependent tumors and can treat locally advanced BCC patients who are not candidates for surgery or radiation therapy. The BOLT clinical trials were conducted to evaluate the efficacy/potency of sonidegib in the treatment of advanced BCC or metastatic BCC. The patients were randomized in 1:2 ratios to receive 200 or 800 mg oral sonidegib daily, stratified by disease, histological subtype and geographical region...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28150447/chemotherapy-induced-alopecia-management-clinical-experience-and-practical-advice
#2
Alfredo Rossi, Maria Caterina Fortuna, Gemma Caro, Giulia Pranteda, Valentina Garelli, Umberto Pompili, Marta Carlesimo
BACKGROUND: Chemotherapy-induced alopecia (CIA) is probably one of the most shocking aspects for oncological patients and underestimated by physicians. Among hair loss risk factors, there are treatment-related aspects such as drug dose, administration regimen, and exposure to X-rays, but also patient-related characteristics. To the best of our knowledge, no guidelines are available about CIA management. AIMS AND METHODS: With this study, based on literature background and our clinical experience, we would like to propose a list of actions in order to estimate the risk of hair loss before starting chemotherapy and to manage this condition before, during, and after drug administration and to create a sort of practical guide for dermatologists and oncologists...
February 2, 2017: Journal of Cosmetic Dermatology
https://www.readbyqxmd.com/read/28094753/quantifying-cutaneous-adverse-effects-of-systemic-glucocorticoids-in-patients-with-rheumatoid-arthritis-a-cross-sectional-cohort-study
#3
Jonna Amann, Anne-Marie Wessels, Friederike Breitenfeldt, Dörte Huscher, Johannes W J Bijlsma, Johannes W G Jacobs, Frank Buttgereit
OBJECTIVES: EULAR guidelines state that adverse effects (AEs) of glucocorticoid (GC) therapy should be considered and discussed with the patient before treatment is initiated. However, reliable quantitative data, especially on cutaneous AEs of low-to-medium dose GCs are lacking. We performed a study assessing the occurrence of cutaneous AEs of GCs and its association with current and cumulative GC doses in patients with rheumatoid arthritis (RA). METHODS: In a cross-sectional study performed in 2 outpatient rheumatology centres, 381 RA patients were enrolled...
January 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27931749/-hereditary-epidermolysis-bullosa-french-national-guidelines-pnds-for-diagnosis-and-treatment
#4
C Chiaverini, E Bourrat, J Mazereeuw-Hautier, S Hadj-Rabia, C Bodemer, J-P Lacour
Hereditary epidermolysis bullosa (EB) is a heterogeneous group of rare genetic diseases characterized by fragile skin and/or mucous membrane, and it may be either local or generalized. It is caused by mutations in genes encoding different proteins involved mainly in the structure and function of the dermal-epidermal junction. Nineteen genes have so far been identified. They are classified by level of skin cleavage (from top to bottom) into four groups: EB simplex, junctional EB, dystrophic EB and Kindler syndrome...
January 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/27789379/a-new-label-free-screen-for-steroid-5%C3%AE-reductase-inhibitors-using-lc-ms
#5
Jukkarin Srivilai, Karma Rabgay, Nantaka Khorana, Neti Waranuch, Nitra Nuengchamnong, Kornkanok Ingkaninan
Steroid 5α-reductase (S5αR) plays an important role in metabolizing testosterone into active androgen dihydrotestosterone (DHT) which is involved in many androgen dependent disorders, such as androgenic alopecia, benign prostatic hyperplasia and acne. The method for screening for S5αR inhibition is key in finding new antagonists. In this study, the label-free S5αR inhibitory assay using LC-MS was developed. S5αR type 1 enzyme was obtained from LNCaP prostate cancer cells. The enzymatic assay was optimised for enzyme-substrate (testosterone) concentration, NADPH-cofactor concentration, solvent tolerance, enzyme activity stability and incubation time...
December 2016: Steroids
https://www.readbyqxmd.com/read/27601857/female-pattern-hair-loss-a-retrospective-study-in-a-tertiary-referral-center
#6
Tee Wei Siah, Llorenia Muir-Green, Jerry Shapiro
BACKGROUND: Female pattern hair loss (FPHL) is a very common problem in women. The underlying pathophysiology remains unclear, and there are no universally agreed treatment guidelines. OBJECTIVE: We explored the clinical features, relevant medical and family history, laboratory evaluation, and treatment and compliance of 210 patients with FPHL. METHODS: Data analysis from case notes was performed on 210 patients with a diagnosis of FPHL seen from January 2011 to December 2011...
April 2016: International Journal of Trichology
https://www.readbyqxmd.com/read/27581783/adverse-effects-of-voriconazole-over-a-decade-of-use
#7
REVIEW
Miriam T Levine, Pranatharthi H Chandrasekar
Voriconazole use has increased since the drug's introduction in 2002, and new and unique adverse effects are emerging as patients undergo prolonged therapy. Most concerning is the increased risk of cutaneous malignancies, primarily squamous cell carcinoma (SCC); this risk is duration dependent and the associated malignancies tend to be more aggressive and multifocal. Voriconazole is also associated with phototoxicity (which may be a precursor to malignancy), periostitis, hallucinations and encephalopathy, peripheral neuropathy, alopecia, nail changes, hyponatremia, and other adverse effects...
November 2016: Clinical Transplantation
https://www.readbyqxmd.com/read/27530764/micro-needling-depth-penetration-presence-of-pigment-particles-and-fluorescein-stained-platelets-clinical-usage-for-aesthetic-concerns
#8
Gordon H Sasaki
BACKGROUND: Aesthetic micro-needling (MN) has demonstrated skin permeability to cosmeceutical ingredients and platelet-rich plasma by creating reversible micro-channels in the skin. OBJECTIVES: The purposes of this study were to determine: (1) actual needle depth-penetrations by adjusting needle lengths in a disposable tip of an electric MN device; (2) time-dependent passage of pigment and platelets; and (3) safety and efficacy profiles in patients. METHODS: Excised micro-needled pre-auricular skin was used to determine actual depths of tissue penetration with six needle lengths, and the presence of massaged pigment particles (histological examination) and fluorescein-labeled platelets (confocal laser microscopy) in 1 mm depth micro-channels over an hour...
January 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/27504707/the-diagnosis-and-treatment-of-hair-and-scalp-diseases
#9
Hans Wolff, Tobias W Fischer, Ulrike Blume-Peytavi
BACKGROUND: Hair loss is caused by a variety of hair growth disorders, each with its own pathogenetic mechanism. METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed, on the current German and European guidelines, and on the authors' clinical and scientific experience. RESULTS: Excessive daily hair loss (effluvium) may be physiological, as in the postpartum state, or pathological, due for example to thyroid disturbances, drug effects, iron deficiency, or syphilis...
May 27, 2016: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/27502902/chromatographic-method-for-clobetasol-propionate-determination-in-hair-follicles-and-in-different-skin-layers
#10
Tamara Ângelo, Marcílio S S Cunha-Filho, Guilherme M Gelfuso, Tais Gratieri
Clobetasol propionate (CLO) is a potent steroid used for the treatment of several dermatological diseases. Recent studies suggest its additional use in alopecia topical treatment, generating a demand for novel formulations with specific delivery into hair follicles. Hence, a selective analytical method for drug quantification in follicular structures and skin layers is required. For this, a simple HPLC-UV method was developed. Quantification was performed using a RP-C18 column (4.6 mm × 15 cm, 5 μm), with a mixture of methanol-acetonitrile-water (50:15:35 v/v) as mobile phase, a flow rate of 1...
February 2017: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/27377548/use-and-misuse-of-common-terminology-criteria-for-adverse-events-in-cancer-clinical-trials
#11
Sheng Zhang, Fei Liang, Ian Tannock
BACKGROUND: Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) were released in 2003 and have been used widely to report toxicity in publications or presentations describing cancer clinical trials. Here we evaluate whether guidelines for reporting toxicity are followed in publications reporting randomized clinical trials (RCTs) for cancer. METHODS: Phase III RCTs evaluating systemic cancer therapy published between 2011 and 2013, were reviewed to identify eligible studies, which stated explicitly that CTCAE v3...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27269276/lisinopril-induced-alopecia-a-case-report
#12
Vivek Kataria, Hueyyoung Wang, Joyce W Wald, Yvonne L Phan
The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines consider angiotensin-converting enzyme (ACE) inhibitors as one of the mainstay therapies in the management of heart failure. The widespread use of ACE inhibitors has been associated with several notable adverse effects such as hyperkalemia and an increased serum creatinine. There are no previous reports of alopecia associated with lisinopril use; however, a few previous cases of alopecia associated with other ACE inhibitors exist...
June 6, 2016: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/27114262/all-hairstyles-are-not-created-equal-what-the-dermatologist-needs-to-know-about-black-hairstyling-practices-and-the-risk-of-traction-alopecia-ta
#13
REVIEW
Alessandra Haskin, Crystal Aguh
Prevalent among black women, traction alopecia (TA) is a type of hair loss that is often attributed to certain hairstyling practices. Although some of the hair care techniques common in the black community can promote ease of everyday hairstyling for black women, many of these practices have been implicated as risk factors for TA. Because of the limited literature on black hairstyling methods, hair loss in this patient population can present a diagnostic and therapeutic challenge for dermatologists. By increasing the knowledge and understanding of these practices and their risk of causing TA, clinicians can better manage this condition and stop the progression of hair loss before it becomes permanent...
September 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/26924401/guidelines-on-the-use-of-finasteride-in-androgenetic-alopecia
#14
REVIEW
Venkataram Mysore, B M Shashikumar
BACKGROUND: Finasteride is a widely used drug in dermatology for the treatment of androgenetic alopecia. There are many reports of associated sexual side effects. This article reviews the use of once-daily 1 mg finasteride in androgenetic alopecia and its associated sexual adverse effects. METHODS: A literature search was performed to collect data on the use of finasteride in male pattern baldness. Relevant literature published till March 2014 was obtained from MEDLINE, EMBASE, CINAHL, Cochrane registers and LILACS...
March 2016: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/26813455/sorafenib-in-combination-with-transarterial-chemoembolization-for-hepatocellular-carcinoma-a-meta-analysis
#15
REVIEW
M-D Hu, L-H Jia, H-B Liu, K-H Zhang, G-H Guo
OBJECTIVE: This meta-analysis aimed to analyze the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Electronic data bases were searched for studies (1) enrolled HCC patients undergoing TACE; (2) with sorafenib therapy and control arm of no sorafenib therapy were included for meta-analysis and meta-regression; (3) studies without control arm were included for data review and (4) had time to progression (TTP) and overall survival (OS) or relative outcome of HCC as the endpoint...
2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/26509855/american-association-of-clinical-endocrinologists-american-college-of-endocrinology-and-androgen-excess-and-pcos-society-disease-state-clinical-review-guide-to-the-best-practices-in-the-evaluation-and-treatment-of-polycystic-ovary-syndrome-part-1
#16
Neil F Goodman, Rhoda H Cobin, Walter Futterweit, Jennifer S Glueck, Richard S Legro, Enrico Carmina
Polycystic Ovary Syndrome (PCOS) is recognized as the most common endocrine disorder of reproductive-aged women around the world. This document, produced by the collaboration of the American Association of Clinical Endocrinologists (AACE) and the Androgen Excess and PCOS Society (AES) aims to highlight the most important clinical issues confronting physicians and their patients with PCOS. It is a summary of current best practices in 2015. PCOS has been defined using various criteria, including menstrual irregularity, hyperandrogenism, and polycystic ovary morphology (PCOM)...
November 2015: Endocrine Practice
https://www.readbyqxmd.com/read/26507460/appraisal-of-guidelines-for-androgenetic-alopecia-using-the-appraisal-of-guidelines-for-research-and-evaluation-ii-instrument
#17
Mengya Huang, Xun Zhou
RATIONALE, AIMS AND OBJECTIVES: The purpose of this study is to systematically evaluate the quality of methodological guidelines for androgenetic alopecia (AGA) using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument by searching and analysing the available worldwide guidelines. This could provide a reference for selecting clinical guidelines and for developing new guidelines in the future. METHODS: We searched PubMed and other electronic databases for any AGA guidelines published until 2014...
December 2015: Journal of Evaluation in Clinical Practice
https://www.readbyqxmd.com/read/26463243/biologic-therapy-in-inflammatory-and-immunomediated-skin-diseases-safety-profile
#18
REVIEW
Giulia Ganzetti, Anna Campanati, E Molinelli, A Offidani
Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis. Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa. Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series...
2016: Current Drug Safety
https://www.readbyqxmd.com/read/26383179/-new-populations-at-increased-cardiovascular-risk-cardiovascular-disease-in-dermatological-diseases
#19
Elena Godoy-Gijón, Carmen Meseguer-Yebra, Lucía Palacio-Aller, Diego Vicente Godoy-Rocati, Carlos Lahoz-Rallo
The increased cardiovascular risk in some dermatological diseases has been demonstrated in recent decades. Diseases such as psoriasis and systemic lupus erythematosus are currently included in the guidelines for prevention of cardiovascular disease. Other diseases such as androgenic alopecia, polycystic ovary syndrome, hidradenitis suppurativa or lichen planus have numerous studies that point to an increased risk, however, they have not been included in these guidelines. In this article we review the evidence supporting this association, in order to alert the clinician to the need for greater control in cardiovascular risk factors in these patients...
May 2016: Clínica e Investigación en Arteriosclerosis
https://www.readbyqxmd.com/read/26235375/t-helper-17-cytokines-interleukins-17-21-22-and-6-and-tumor-necrosis-factor-%C3%AE-in-patients-with-alopecia-areata-association-with-clinical-type-and-severity
#20
Mona A Atwa, Nahed Youssef, Nervana M Bayoumy
BACKGROUND: Alopecia areata (AA) is an organ-specific autoimmune disease characterized by T-cell infiltrates and cytokine production. T-helper 17 (Th17) cells are crucially involved in the pathogenesis of autoimmune diseases. OBJECTIVES: Our aim was to assess the association of Th17 with AA. We examined interleukin (IL)-17, IL-21, IL-22, IL-6, and tumor necrosis factor-alpha (TNF-α) levels in the serum of patients with AA and studied their association with clinical type and severity of AA...
June 2016: International Journal of Dermatology
keyword
keyword
75159
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"